Literature DB >> 33673461

Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring.

Ivana Martins1, Ilda Patrícia Ribeiro1,2,3,4, Joana Jorge2,3,4,5, Ana Cristina Gonçalves2,3,4,5, Ana Bela Sarmento-Ribeiro2,3,4,5,6, Joana Barbosa Melo1,2,3,4, Isabel Marques Carreira1,2,3,4.   

Abstract

The minimally-or non-invasive detection of circulating tumor-derived components in biofluids, such as blood, liquid biopsy is a revolutionary approach with significant potential for the management of cancer. Genomic and transcriptomic alterations can be accurately detected through liquid biopsies, which provide a more comprehensive characterization of the heterogeneous tumor profile than tissue biopsies alone. Liquid biopsies could assist diagnosis, prognosis, and treatment selection, and hold great potential to complement current surveilling strategies to monitor disease evolution and treatment response in real-time. In particular, these are able to detect minimal residual disease, to predict progression, and to identify mechanisms of resistance, allowing to re-orient treatment strategies in a timelier manner. In this review we gathered current knowledge regarding the role and potential of liquid biopsies for the diagnosis and follow-up of cancer patients. The presented findings emphasize the strengths of liquid biopsies, revealing their chance of improving the diagnosis and monitoring of several tumor types in the near future. However, despite growing evidence supporting their value as a management tool in oncology, some limitations still need to be overcome for their implementation in the routine clinical setting.

Entities:  

Keywords:  cancer; cell-free DNA; circulating tumor cells; diagnosis; liquid biopsies; monitoring; precision medicine; prognosis

Mesh:

Substances:

Year:  2021        PMID: 33673461      PMCID: PMC7997281          DOI: 10.3390/genes12030349

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  90 in total

1.  Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC.

Authors:  F Xie; P Li; J Gong; H Tan; J Ma
Journal:  Clin Transl Oncol       Date:  2017-09-27       Impact factor: 3.405

2.  Metabolic Alterations as a Signpost to Early Pancreatic Cancer.

Authors:  Natalia Khalaf; Brian M Wolpin
Journal:  Gastroenterology       Date:  2019-03-26       Impact factor: 22.682

3.  Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.

Authors:  Lee-Ann Tjon-Kon-Fat; Marie Lundholm; Mona Schröder; Thomas Wurdinger; Camilla Thellenberg-Karlsson; Anders Widmark; Pernilla Wikström; Rolf Jonas Andreas Nilsson
Journal:  Prostate       Date:  2017-11-02       Impact factor: 4.104

4.  Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma.

Authors:  Matthew Egyud; Mohamedtaki Tejani; Arjun Pennathur; James Luketich; Praveen Sridhar; Emiko Yamada; Anders Ståhlberg; Stefan Filges; Paul Krzyzanowski; Jennifer Jackson; Irina Kalatskaya; Wei Jiao; Gradon Nielsen; Zhongren Zhou; Virginia Litle; Lincoln Stein; Tony Godfrey
Journal:  Ann Thorac Surg       Date:  2019-05-03       Impact factor: 4.330

5.  Rapid clearance of fetal DNA from maternal plasma.

Authors:  Y M Lo; J Zhang; T N Leung; T K Lau; A M Chang; N M Hjelm
Journal:  Am J Hum Genet       Date:  1999-01       Impact factor: 11.025

6.  Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.

Authors:  Annette R Kodahl; Sidse Ehmsen; Niels Pallisgaard; Anne M B Jylling; Jeanette D Jensen; Anne-Vibeke Laenkholm; Ann S Knoop; Henrik J Ditzel
Journal:  Mol Oncol       Date:  2018-05-04       Impact factor: 6.603

7.  Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.

Authors:  Patrice Hodonou Avogbe; Arnaud Manel; Emmanuel Vian; Geoffroy Durand; Nathalie Forey; Catherine Voegele; Maria Zvereva; Md Ismail Hosen; Sonia Meziani; Berengere De Tilly; Gilles Polo; Olesia Lole; Pauline Francois; Tiffany Myriam Delhomme; Christine Carreira; Sara Monteiro-Reis; Rui Henrique; Behnoush Abedi-Ardekani; Graham Byrnes; Matthieu Foll; Elisabete Weiderpass; James McKay; Carmen Jeronimo; Ghislaine Scelo; Florence Le Calvez-Kelm
Journal:  EBioMedicine       Date:  2019-05-20       Impact factor: 8.143

8.  Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.

Authors:  Daniel Fernandez-Garcia; Allison Hills; Karen Page; Robert K Hastings; Bradley Toghill; Kate S Goddard; Charlotte Ion; Olivia Ogle; Anna Rita Boydell; Kelly Gleason; Mark Rutherford; Adrian Lim; David S Guttery; R Charles Coombes; Jacqueline A Shaw
Journal:  Breast Cancer Res       Date:  2019-12-19       Impact factor: 6.466

9.  Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia.

Authors:  Arnulf Willms; Clara Müller; Henrike Julich; Niklas Klein; Robert Schwab; Christoph Güsgen; Ines Richardsen; Sebastian Schaaf; Marcin Krawczyk; Marek Krawczyk; Frank Lammert; Detlef Schuppan; Veronika Lukacs-Kornek; Miroslaw Kornek
Journal:  Oncotarget       Date:  2016-05-24

10.  Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.

Authors:  Xin Hong; Ryan J Sullivan; Mark Kalinich; Tanya Todorova Kwan; Anita Giobbie-Hurder; Shiwei Pan; Joseph A LiCausi; John D Milner; Linda T Nieman; Ben S Wittner; Uyen Ho; Tianqi Chen; Ravi Kapur; Donald P Lawrence; Keith T Flaherty; Lecia V Sequist; Sridhar Ramaswamy; David T Miyamoto; Michael Lawrence; Mehmet Toner; Kurt J Isselbacher; Shyamala Maheswaran; Daniel A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-16       Impact factor: 11.205

View more
  23 in total

1.  Microfluidics for the Isolation and Detection of Circulating Tumor Cells.

Authors:  Jessica Sierra-Agudelo; Romen Rodriguez-Trujillo; Josep Samitier
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  KRAS Gene Copy Number as a Negative Predictive Biomarker for the Treatment of Metastatic Rectal Cancer With Cetuximab: A Case Report.

Authors:  Qunli Xiong; Zhu Zeng; Yang Yang; Ya Wang; Yongfeng Xu; Ying Zhou; Jinlu Liu; Zhiwei Zhang; Meng Qiu; Qing Zhu
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

Review 3.  The Utility of Repetitive Cell-Free DNA in Cancer Liquid Biopsies.

Authors:  Ugur Gezer; Abel J Bronkhorst; Stefan Holdenrieder
Journal:  Diagnostics (Basel)       Date:  2022-06-01

4.  Human Blood Platelets Adsorption on Polymeric Materials for Liquid Biopsy.

Authors:  Cristina Potrich; Francesca Frascella; Valentina Bertana; Mario Barozzi; Lia Vanzetti; Federico Piccoli; Attilio Fabio Cristallo; Natalia Malara; Candido Fabrizio Pirri; Cecilia Pederzolli; Lorenzo Lunelli
Journal:  Sensors (Basel)       Date:  2022-06-24       Impact factor: 3.847

5.  Technical considerations in PCR-based assay design for diagnostic DNA methylation cancer biomarkers.

Authors:  Maartje Massen; Kim Lommen; Kim A D Wouters; Johan Vandersmissen; Wim van Criekinge; James G Herman; Veerle Melotte; Leo J Schouten; Manon van Engeland; Kim M Smits
Journal:  Clin Epigenetics       Date:  2022-04-27       Impact factor: 7.259

Review 6.  In vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivity.

Authors:  Gianluigi De Renzi; Giulia De Marco; Michela De Meo; Eleonora Del Rosso; Paola Gazzaniga; Chiara Nicolazzo
Journal:  Cancer Drug Resist       Date:  2022-03-16

7.  Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.

Authors:  Ho Won Kang; Young Joon Byun; Sung Min Moon; Kyeong Kim; Xuan-Mei Piao; Chuang-Ming Zheng; Sung-Kwon Moon; Yung Hyun Choi; Won Tae Kim; Yong-June Kim; Sang-Cheol Lee; Seok Joong Yun; Wun-Jae Kim
Journal:  Investig Clin Urol       Date:  2022-03

Review 8.  Next-Generation Intelligent MXene-Based Electrochemical Aptasensors for Point-of-Care Cancer Diagnostics.

Authors:  Arpana Parihar; Ayushi Singhal; Neeraj Kumar; Raju Khan; Mohd Akram Khan; Avanish K Srivastava
Journal:  Nanomicro Lett       Date:  2022-04-11

Review 9.  Specific study of biological tumor cytology: a narrative review.

Authors:  Yu Ma; Juan He; Zhihui Li
Journal:  Transl Cancer Res       Date:  2021-08       Impact factor: 1.241

Review 10.  On the Relationship of Viral Particles and Extracellular Vesicles: Implications for Viral Vector Technology.

Authors:  Christoph Metzner; Marianne Zaruba
Journal:  Viruses       Date:  2021-06-26       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.